SS Innovations International (NASDAQ: SSII) announced significant growth in the adoption of its SSi Mantra surgical robotic system, with cumulative procedures climbing to 14,103 as of September 8, 2026. That figure represents a 79% increase from 7,885 procedures at the end of 2025, according to a company update issued September 10. The installed base of SSi Mantra systems rose to 238, up 42% from 168 at year-end, and now spans 12 countries following recent launches in Colombia and Sri Lanka.
The expansion into new markets and the sharp rise in procedure volume underscore the company’s growing footprint in the global surgical robotics sector. Approximately 1,500 physicians have been trained on the SSi Mantra system, which has been used in a widening range of surgical applications. Pediatric use is also expanding, including a robotic kidney procedure performed on a 45-day-old infant in India using 5-millimeter instruments. Such cases highlight the system’s potential for minimally invasive surgery in very young patients, a technically demanding area where few robotic platforms are deployed.
Beyond conventional surgeries, SS Innovations reported 188 cumulative robotic telesurgeries as of August 31. These long-distance procedures connect surgeons and patients across countries, demonstrating the system’s tele-surgery capabilities. The company believes this feature could help extend specialized surgical care to underserved regions, though broader adoption will depend on regulatory clearances and infrastructure.
Regulatory milestones are on the horizon. SS Innovations expects the U.S. Food and Drug Administration to complete review of its 510(k) submission by the end of the first quarter of 2027. The company also believes it could obtain EU CE marking for the SSi Mantra by the end of 2026. Securing these approvals would open major markets and likely accelerate installations and procedure counts further.
For investors and industry observers, the update offers concrete metrics on commercial traction. The 79% procedure growth and 42% installation growth since the start of 2026 suggest that SS Innovations is moving beyond early adoption. The company’s progress is detailed in its latest newsroom at https://ibn.fm/SSII, and a full release is available at www.newmediawire.com. Additional details on the company can be found at SS Innovations International (NASDAQ: SSII).
As with any forward-looking announcement, risks remain. The company notes that actual results may differ materially due to factors beyond management’s control, including those described in its SEC filings. Nonetheless, the latest figures provide a clear snapshot of a company scaling its technology across borders and surgical specialties.
